[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Jamali M, Serra S, Chetty R: Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report. JOP; 2007;8(3):330-4
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report.
  • CONTEXT: In as much as no such variant of this pancreatic tumour has been previously reported in the literature, we report an unusual case of an adenosquamous carcinoma of the pancreas characterized by clear cells and rhabdoid cells.
  • Imaging of the abdomen showed a solid mass with cystic components in the region of the uncinate process of the pancreas.
  • Endoscopic retrograde pancreatography showed mild to moderate dilatation of the intrapancreatic biliary tract and of the pancreatic duct, and a biliary stent was placed.
  • Histological evaluation of the pancreatic mass revealed an adenosquamous carcinoma displaying both clear cell and rhabdoid components.
  • CONCLUSIONS: Assessing the predominant histology of pancreatic adenosquamous carcinoma variants such as those characterized by clear cells and rhabdoid cells may help select and improve upon therapies in this aggressive lesion.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology. Rhabdoid Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495363.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Alwaheeb S, Chetty R: Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells. J Clin Pathol; 2005 Sep;58(9):987-90
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas with an acantholytic pattern together with osteoclast-like and pleomorphic giant cells.
  • Imaging of the abdomen showed a mass in the region of the head of the pancreas.
  • Histological evaluation of the pancreatic tumour showed an adenosquamous carcinoma (predominantly composed of squamous carcinoma), which was extensively infiltrative with perineural invasion and involvement of peripancreatic lymph nodes.
  • Areas of pancreatic intraepithelial neoplasia grade III and merging of the squamous and adenocarcinoma components were evident.
  • Unusual histological features that characterised this case included a pronounced acantholytic pattern within the squamous carcinoma component, and the presence of both osteoclastic and pleomorphic giant cells.
  • Giant cells have not been documented previously in association with an adenosquamous carcinoma.
  • Although an acantholytic pattern has been noted in squamous carcinomas in other sites, this is the first report of such a pattern in an adenosquamous carcinoma of the pancreas.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Giant Cells / pathology. Osteoclasts / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2000 Oct;31(10):1223-9 [11070115.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] JOP. 2004 Jul;5(4):220-4 [15254351.001]
  • [Cites] Cancer. 1972 May;29(5):1133-40 [5021607.001]
  • [Cites] J Surg Oncol. 1973;5(4):335-58 [4355621.001]
  • [Cites] J Surg Oncol. 1980;14(3):261-5 [7392648.001]
  • [Cites] Gastroenterology. 1982 Dec;83(6):1297-9 [7129033.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(3):247-53 [3124345.001]
  • [Cites] Gan No Rinsho. 1990 May;36(6):728-32 [2348561.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):618-22 [1864595.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):703-6 [1592394.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • [Cites] Pathology. 1993 Oct;25(4):420-2 [8165013.001]
  • [Cites] Int J Pancreatol. 1995 Oct;18(2):169-75 [8530833.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Pathol Res Pract. 1998;194(8):587-94; discussion 595 [9779494.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] AMA Arch Pathol. 1954 Aug;58(2):101-11 [13170907.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] Pathol Int. 2000 Jul;50(7):562-7 [10886741.001]
  • (PMID = 16126885.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770836
  •  go-up   go-down


3. Okabayashi T, Hanazaki K: Surgical outcome of adenosquamous carcinoma of the pancreas. World J Gastroenterol; 2008 Nov 28;14(44):6765-70
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of adenosquamous carcinoma of the pancreas.
  • Adenosquamous carcinoma is rare, accounting for 3%-4% of all pancreatic carcinoma cases.
  • These tumors are characterized by the presence of variable proportions of mucin-producing glandular elements and squamous components, the latter of which should account for at least 30% of the tumor tissue.
  • Recently, several reports have described cases of adenosquamous carcinoma of the pancreas.
  • However, as the number of patients who undergo resection at a single institute is limited, large studies describing the clinicopathological features, therapeutic management, and surgical outcome for adenosquamous carcinoma of the pancreas are lacking.
  • We performed a literature review of English articles retrieved from Medline using the keywords 'pancreas' and 'adenosquamous carcinoma'.
  • Our subsequent review of the literature revealed that optimal adjuvant chemotherapy and/or radiotherapy regimens for adenosquamous carcinoma of the pancreas have not been established, and that curative surgical resection offers the only chance for long-term survival.
  • Unfortunately, the prognosis of the 39 patients who underwent pancreatic resection for adenosquamous carcinoma was very poor, with a 3-year overall survival rate of 14.0% and a median survival time of 6.8 mo.
  • Since the postoperative prognosis of adenosquamous carcinoma of the pancreas is currently worse than that of pancreatic adenocarcinoma, new adjuvant chemotherapies and/or radiation techniques should be investigated as they may prove indispensible to the improvement of surgical outcomes.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] Ann Surg. 2008 Mar;247(3):456-62 [18376190.001]
  • [Cites] Pathologica. 2000 Oct;92(5):323-6 [11198466.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] Int J Pancreatol. 2001;29(1):53-8 [11558633.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] J Gastroenterol. 2003;38(12):1171-5 [14714256.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1192-6 [7214302.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] J Surg Oncol. 1991 Jun;47(2):109-16 [2062081.001]
  • [Cites] J Surg Oncol. 1992 Jan;49(1):58-62 [1372374.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):415-22 [1319814.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2739-42 [7872711.001]
  • [Cites] Surg Today. 1995;25(9):843-7 [8555707.001]
  • [Cites] J Gastroenterol. 1995 Dec;30(6):798-802 [8963403.001]
  • [Cites] J Surg Oncol. 1997 Feb;64(2):159-62 [9047255.001]
  • [Cites] Ann Nucl Med. 1997 Feb;11(1):41-3 [9095322.001]
  • [Cites] Gastrointest Endosc. 1998 May;47(5):410-3 [9609438.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1167-70 [9672355.001]
  • [Cites] Acta Cytol. 1998 Nov-Dec;42(6):1451-4 [9850660.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] Pancreatology. 2005;5(4-5):438-42 [15985769.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):987-90 [16126885.001]
  • [Cites] Digestion. 2005;72(2-3):104-8 [16172546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1060-6 [15978737.001]
  • [Cites] World J Gastroenterol. 2006 Jul 28;12(28):4466-72 [16874856.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] JOP. 2007;8(3):330-4 [17495363.001]
  • [Cites] Hepatogastroenterology. 2007 Mar;54(74):564-9 [17523323.001]
  • [Cites] Am J Gastroenterol. 2007 Jul;102(7):1377-82 [17403071.001]
  • [Cites] Abdom Imaging. 2000 Jul-Aug;25(4):420-3 [10926197.001]
  • (PMID = 19058301.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] China
  • [Number-of-references] 40
  • [Other-IDs] NLM/ PMC2773870
  •  go-up   go-down


Advertisement
4. Brody JR, Costantino CL, Potoczek M, Cozzitorto J, McCue P, Yeo CJ, Hruban RH, Witkiewicz AK: Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol; 2009 May;22(5):651-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma.
  • Adenosquamous carcinoma of the pancreas is one of the most aggressive forms of pancreatic cancer.
  • Understanding the common molecular and pathologic features of pancreatic adenosquamous carcinomas could provide critical information for identifying therapeutic targets.
  • Herein, we analyzed the pathologic and molecular features of our series of eight pancreatic adenosquamous carcinomas.
  • The majority of the cases had loss of Dpc4 protein and strong nuclear p53 positivity, similar to the molecular signature found in pancreatic ductal adenocarcinoma.
  • The squamous component was positive for p63 staining and thus p63 labeling was helpful in identifying squamous differentiation in adenosquamous carcinomas with an acantholytic growth pattern.
  • In summary, although pancreatic adenosquamous carcinoma and ductal adenocarcinoma have overlapping pathologic and molecular characteristics, there are distinct differences that may be helpful in diagnostic and therapeutic strategies.
  • [MeSH-major] Carcinoma, Adenosquamous / genetics. Carcinoma, Pancreatic Ductal / genetics. DNA-Binding Proteins / genetics. Pancreatic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Smad4 Protein / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19270646.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / KRAS protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / TP53TG1 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


5. Hsu JT, Yeh CN, Chen YR, Chen HM, Hwang TL, Jan YY, Chen MF: Adenosquamous carcinoma of the pancreas. Digestion; 2005;72(2-3):104-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas.
  • BACKGROUND/AIMS: Adenosquamous carcinoma (ASC) of the pancreas is rare and correct preoperative diagnosis is difficult.
  • Case reports of ASC of the pancreas are sporadic and have typically employed small series.
  • This study investigated the clinicopathological features of 7 cases of ASC of the pancreas and reviewed the pertinent literature to elucidate this rare disease.
  • METHODOLOGY: Seven patients (4 men and 3 women; age range 38-79 years; median 66 years) with ASC of the pancreas who underwent surgical treatment at Chang Gung Memorial Hospital between February 1993 and April 2000 were retrospectively reviewed.
  • The tumors were located at the head of the pancreas in 4 patients (57.1%), at the body in 2, and at the tail in 2.
  • CONCLUSIONS: Patients with ASC present symptoms similar to those of adenocarcinoma of the pancreas.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16172546.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


6. Skafida E, Grammatoglou X, Glava C, Zissis D, Paschalidis N, Katsamagkou E, Firfiris N, Vasilakaki T: Adenosquamous carcinoma of the pancreas: a case report. Cases J; 2010;3:41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas: a case report.
  • Adenosquamous carcinoma of the pancreas is a rare variant of pancreatic exocrine carcinoma.
  • Imaging of the abdomen showed a mass in the region of the head of the pancreas.
  • Histological evaluation of the pancreatic tumor showed an adenosquamous carcinoma which was extensively infiltrative with perineural invasion, involvement of peripancreatic lymph nodes and all the thickness of the duodenum wall.
  • The tumor exhibited a biphasic malignant growth identified as well to moderate differentiated adenocarcinoma and well to poorly differentiated squamous cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2008 Sep;207(3):368-70 [18722942.001]
  • [Cites] Digestion. 2005;72(2-3):104-8 [16172546.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):987-90 [16126885.001]
  • [Cites] J Gastroenterol. 2003;38(12):1171-5 [14714256.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Int J Pancreatol. 2001;29(1):53-8 [11558633.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] Abdom Imaging. 2000 Jul-Aug;25(4):420-3 [10926197.001]
  • [Cites] Arch Pathol Lab Med. 2000 Feb;124(2):212-5 [10656728.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • (PMID = 20205828.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2825199
  •  go-up   go-down


7. Smoot RL, Zhang L, Sebo TJ, Que FG: Adenosquamous carcinoma of the pancreas: a single-institution experience comparing resection and palliative care. J Am Coll Surg; 2008 Sep;207(3):368-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas: a single-institution experience comparing resection and palliative care.
  • BACKGROUND: Adenosquamous carcinoma is a rare malignancy of the exocrine pancreas.
  • STUDY DESIGN: Records were reviewed for patients with adenosquamous pancreatic cancer evaluated during the years 1985 to 2003.
  • RESULTS: Twenty-three patients were identified with adenosquamous carcinoma of the pancreas.
  • CONCLUSIONS: The retrospective review of our single-institution experience with resection and palliative care for adenosquamous cancer of the pancreas has demonstrated a longer survival for patients that can undergo an R0 resection.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Palliative Care. Pancreatectomy. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722942.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Voong KR, Davison J, Pawlik TM, Uy MO, Hsu CC, Winter J, Hruban RH, Laheru D, Rudra S, Swartz MJ, Nathan H, Edil BH, Schulick R, Cameron JL, Wolfgang CL, Herman JM: Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol; 2010 Jan;41(1):113-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients.
  • Pancreatic adenosquamous carcinoma is a rare morphological variant of pancreatic adenocarcinoma with an especially poor prognosis.
  • The purpose of this study is to identify clinicopathologic features associated with prognosis, assess whether the percentage of squamous differentiation in pancreatic adenosquamous carcinoma is associated with an inferior prognosis, and examine the impact of adjuvant chemoradiation therapy on overall survival.
  • Forty-five (1.2%) of 3651 patients who underwent pancreatic resection at the Johns Hopkins Hospital, Baltimore, MD, between 1986 and 2007 were identified with adenocarcinoma of the pancreas with any squamous differentiation.
  • Seventy-six percent of carcinomas were node positive, 37% were margin-positive resections, and 68% had 30% or more squamous differentiation.
  • Median overall survival of the pancreatic adenosquamous carcinoma cohort was 10.9 months (range, 2.1-140.6 months; 95% confidence interval, 8.2-12.5 months).
  • Adjuvant chemoradiation therapy was associated with superior overall survival in patients with pancreatic adenosquamous carcinoma (P = .005).
  • The proportion of squamous differentiation was not associated with median overall survival (< 30% versus > or = 30%, P = .82).
  • Survival after pancreatic resection of pancreatic adenosquamous carcinoma is poor.
  • The proportion of squamous differentiation in resected pancreatic adenosquamous carcinoma specimens does not appear to impact overall survival.
  • [MeSH-major] Carcinoma, Adenosquamous / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2009 May;22(5):651-9 [19270646.001]
  • [Cites] Acta Cytol. 1984 Nov-Dec;28(6):733-6 [6594886.001]
  • [Cites] Int J Pancreatol. 2001;29(1):53-8 [11558633.001]
  • [Cites] Ultrastruct Pathol. 1982 Jan-Mar;3(1):17-23 [7071952.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] J Gastroenterol. 2003;38(12):1171-5 [14714256.001]
  • [Cites] Cancer. 1972 May;29(5):1133-40 [5021607.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2234-48 [167949.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1192-6 [7214302.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] Abdom Imaging. 2000 Jul-Aug;25(4):420-3 [10926197.001]
  • [Cites] Diagn Cytopathol. 2001 Jul;25(1):38-42 [11466811.001]
  • [Cites] World J Gastroenterol. 2008 Nov 28;14(44):6765-70 [19058301.001]
  • [Cites] World J Surg Oncol. 2008;6:95 [18764955.001]
  • [Cites] J Am Coll Surg. 2008 Sep;207(3):368-70 [18722942.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3503-10 [18640931.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):74-7 [18307024.001]
  • [Cites] Drugs. 2007;67(16):2293-310 [17983252.001]
  • [Cites] JOP. 2007;8(3):330-4 [17495363.001]
  • [Cites] Digestion. 2005;72(2-3):104-8 [16172546.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):987-90 [16126885.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] Acta Cytol. 1998 Nov-Dec;42(6):1451-4 [9850660.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1167-70 [9672355.001]
  • [Cites] Lifetime Data Anal. 1995;1(2):195-204 [9385101.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] J Surg Oncol. 1997 Feb;64(2):159-62 [9047255.001]
  • [Cites] J Surg Oncol. 1991 Jun;47(2):109-16 [2062081.001]
  • [Cites] Diagn Cytopathol. 1986 Jan-Mar;2(1):72-5 [3522134.001]
  • (PMID = 19801164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / T32 CA126607
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS433902; NLM/ PMC3556992
  •  go-up   go-down


9. Kobayashi N, Higurashi T, Iida H, Mawatari H, Endo H, Nozaki Y, Tomimoto A, Yoneda K, Akiyama T, Fujita K, Takahashi H, Yoneda M, Inamori M, Abe Y, Kirikoshi H, Kubota K, Saito S, Ueno N, Nakajima A, Yamanaka S, Inayama Y: Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM). J Hepatobiliary Pancreat Surg; 2008;15(5):531-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM).
  • We report a rare case of adenosquamous carcinoma of the pancreas associated with humoral hypercalcemia of malignancy (HHM) in which parathyroid hormone-related protein (PTH-rP) was identified as the causative factor of hypercalcemia.
  • Abdominal computed tomography demonstrated a large tumor in the body of the pancreas, with multiple liver metastases.
  • Autopsy demonstrated that the neoplasm in the pancreas showed an abrupt histological transition from adenocarcinoma to squamous cell carcinoma.
  • PTH-rP was identified in the primary pancreatic tumor cells by immunohistochemical examination and a reverse-transcription polymerase chain reaction (RTPCR) method.
  • This is a very rare report of adenosquamous cell carcinoma of the pancreas associated with HHM.
  • [MeSH-major] Carcinoma, Adenosquamous / complications. Hypercalcemia / etiology. Pancreatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836809.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein
  •  go-up   go-down


10. Trikudanathan G, Dasanu CA: Adenosquamous carcinoma of the pancreas: a distinct clinicopathologic entity. South Med J; 2010 Sep;103(9):903-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas: a distinct clinicopathologic entity.
  • Among exocrine pancreatic tumors, adenosquamous carcinoma (ASC) is a rare, aggressive subtype with a worse prognosis and a higher potential for metastases compared to its more conventional glandular counterpart, adenocarcinoma.
  • Although such features as central necrosis and hypervascularity are suggestive of pancreatic ASC, more research is necessary to identify other, more specific markers for this tumor subtype.
  • Humoral hypercalcemia of malignancy has also been described with ASC of the pancreas, likely as a result of PTHrP production by the squamous component of the tumor.
  • Similar to the therapeutics of pancreatic adenocarcinoma, adjuvant chemotherapy or chemoradiotherapy is currently indicated for resectable ASC of the pancreas, while gemcitabine or gemcitabine combinations are used for a more advanced disease.
  • Both pathologic and molecular features of pancreatic ASC characterize it as a distinct subtype of pancreatic cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Biomarkers, Tumor. Chemotherapy, Adjuvant. Diagnostic Imaging. Genetic Predisposition to Disease. Humans. Jaundice / etiology. Mutation. Necrosis. Palliative Care. Pancreas / pathology. Pancreatectomy. Risk Factors. Survival Analysis. Weight Loss

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697320.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 43
  •  go-up   go-down


11. Lampropoulos P, Filippou G, Skafida E, Vasilakaki T, Paschalidis N, Rizos S: Adenosquamous carcinoma of the pancreas, a rare tumor entity: a case report. Cases J; 2009;2:9129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the pancreas, a rare tumor entity: a case report.
  • INTRODUCTION: Adenosquamous carcinoma of the pancreas is a rare variant of exocrine pancreatic tumor.
  • Pancreatic carcinoma of the head was diagnosed and a pylorus preserving pancreaticoduodenectomy was performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg Oncol. 2008;6:95 [18764955.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] J Gastroenterol Hepatol. 2008 May;23(5):820 [18410615.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):74-7 [18307024.001]
  • [Cites] World J Surg. 2004 Oct;28(10):1011-8 [15573257.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1167-70 [9672355.001]
  • [Cites] Ann Nucl Med. 1997 Feb;11(1):41-3 [9095322.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2739-42 [7872711.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1192-6 [7214302.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Minerva Chir. 2004 Apr;59(2):99-111 [15238885.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] Int J Pancreatol. 2001;29(1):53-8 [11558633.001]
  • [Cites] J Am Coll Surg. 2008 Sep;207(3):368-70 [18722942.001]
  • (PMID = 20062646.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2803926
  •  go-up   go-down


12. Hsu JT, Chen HM, Wu RC, Yeh CN, Yeh TS, Hwang TL, Jan YY, Chen MF: Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma. World J Surg Oncol; 2008;6:95
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma.
  • BACKGROUND: Pancreatic adenosquamous carcinoma (ASC) is a rare pancreatic malignancy subtype.
  • We investigated the clinicopathological features and outcome of pancreatic ASC patients after surgery.
  • METHODS: The medical records of 12 patients with pancreatic ASC undergoing surgical treatment (1993 to 2006) were retrospectively reviewed.
  • Survival data of patients with stage IIB pancreatic adenocarcinoma and ASC undergoing surgical resection were compared.
  • Tumors were located at pancreatic head in 5 (41.7%) patients, tail in 5 (41.7%), and body in 4 (33.3%).
  • Patients with stage IIB pancreatic ASC had shorter median survival compared to those with adenocarcinoma.
  • CONCLUSION: Aggressive surgical management does not appear effective in treating pancreatic ASC patients.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / surgery. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1963 Nov;22:578-82 [14082276.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] Digestion. 2005;72(2-3):104-8 [16172546.001]
  • [Cites] World J Surg Oncol. 2008;6:9 [18221566.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):372-8 [14681946.001]
  • [Cites] J Gastroenterol. 2003;38(12):1171-5 [14714256.001]
  • [Cites] Cancer. 1968 Nov;22(5):1053-9 [5686635.001]
  • [Cites] Dis Colon Rectum. 1970 Sep-Oct;13(5):390-3 [5472856.001]
  • [Cites] J Surg Oncol. 1973;5(4):335-58 [4355621.001]
  • [Cites] Gastroenterology. 1987 Apr;92(4):1078-82 [3556988.001]
  • [Cites] J Surg Oncol. 1991 Jun;47(2):109-16 [2062081.001]
  • [Cites] J Surg Oncol. 1992 Jan;49(1):58-62 [1372374.001]
  • [Cites] Ann Nucl Med. 1997 Feb;11(1):41-3 [9095322.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Am J Gastroenterol. 1998 Jul;93(7):1167-70 [9672355.001]
  • [Cites] Am J Obstet Gynecol. 1964 May 1;89:121-9 [14155003.001]
  • (PMID = 18764955.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2543014
  •  go-up   go-down


13. Shibagaki K, Fujita K, Nakayama S, Takenaka M, Fukuba N, Matsui S, Ozaka M, Yoshinaga H, Masuzawa A, Watanabe A, Fujiwara H, Sugawara A, Fujita T, Mukai H, Kinoshita Y: Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy. Int J Clin Oncol; 2008 Feb;13(1):74-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy.
  • A 51-year-old woman with an unresectable pancreatic tumor that was histologically diagnosed as an adenosquamous carcinoma underwent chemoradiotherapy with 5-fluourouracil (FU) and low-dose cisplatin (low-dose FP).
  • This report presents the successful use of chemoradiotherapy with low-dose FP and additional combined chemotherapy with S-1 and cisplatin for unresectable pancreatic adenosquamous carcinoma.
  • [MeSH-major] Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gan To Kagaku Ryoho. 2006 Jan;33(1):83-5 [16410703.001]
  • [Cites] J Surg Oncol. 1992 Jan;49(1):58-62 [1372374.001]
  • [Cites] Am Surg. 1978 Apr;44(4):206-9 [646234.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14 (6B):2739-42 [7872711.001]
  • [Cites] Int J Pancreatol. 1999 Oct;26(2):85-91 [10597404.001]
  • [Cites] J Gastroenterol. 1995 Dec;30(6):798-802 [8963403.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] J Pathol. 1985 May;146(1):17-29 [2989468.001]
  • [Cites] Histopathology. 1983 Sep;7(5):645-61 [6313514.001]
  • [Cites] Int J Pancreatol. 2001;29(1):53-8 [11558633.001]
  • [Cites] Arch Surg. 1999 Jun;134(6):599-603 [10367867.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1300-4 [12654441.001]
  • [Cites] Lancet. 1969 Oct 25;2(7626):865-7 [4186452.001]
  • [Cites] Cancer. 1972 May;29(5):1133-40 [5021607.001]
  • [Cites] JAMA. 1985 Apr 12;253(14):2061-7 [2579257.001]
  • [Cites] Ann Oncol. 1993 Apr;4(4):333-6 [8518226.001]
  • [Cites] Mod Pathol. 2001 May;14(5):443-51 [11353055.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Jan;33(1):99-103 [16410707.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Eur J Cancer. 1971 Aug;7(4):307-15 [4328281.001]
  • [Cites] Cancer. 1980 Sep 1;46(5):1192-6 [7214302.001]
  • (PMID = 18307024.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Okabayashi T, Kobayashi M, Nishimori I, Namikawa T, Okamoto K, Onishi S, Araki K: Adenosquamous carcinoma of the extrahepatic biliary tract: clinicopathological analysis of Japanese cases of this uncommon disease. J Gastroenterol; 2005 Feb;40(2):192-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of the extrahepatic biliary tract: clinicopathological analysis of Japanese cases of this uncommon disease.
  • BACKGROUND: We analyzed the clinicopathologic variables and postoperative outcomes in patients with extrahepatic adenosquamous carcinoma to identify important factors for predicting postresection prognosis.
  • METHODS: Thirty-six patients in Japan who underwent surgical resection for adenosquamous carcinoma of the extrahepatic biliary tract, with curative intent by the end of 2003, were studied.
  • A retrospective review, with univariate and multivariate analyses, was performed on the clinical records of patients who underwent surgical exploration for adenosquamous carcinoma of the common bile duct.
  • (1) the presence of pancreatic invasion, (2) the presence of n2 and n3 lymph node metastasis, and (3) curability C status.
  • CONCLUSIONS: Curative surgical resection for adenosquamous carcinoma remains the only effective treatment, because it offers the chance of long-term survival.
  • [MeSH-major] Biliary Tract Neoplasms / pathology. Carcinoma, Adenosquamous / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Japan. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Pancreas / pathology. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770404.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Terada T: Adenosquamous carcinoma in a congenital choledochal cyst associated with pancreatico-biliary maljunction. Pathol Int; 2009 Jul;59(7):482-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma in a congenital choledochal cyst associated with pancreatico-biliary maljunction.
  • Congenital choledochal cyst is occasionally complicated by carcinomatous transformation, mostly adenocarcinoma.
  • Adenosquamous carcinoma arising in a congenital choledochal cyst is very rare.
  • The author herein reports an adenosquamous carcinoma arising in congenital choledochal cyst associated with pancreatico-biliary maljunction.
  • Histologically, the lesion was composed of a squamous cell carcinoma element and an adenocarcinoma element; a gradual transition was recognized between the two.
  • The squamous cell carcinoma element contained microcytic cells with mucins.
  • On immunohistochemistry the adenocarcinoma element and microcytic cells were positive for CEA, but the squamous cell carcinoma element was negative for CEA.
  • Ki-67 labeling was 53% in the adenocarcinoma element and 48% in the squamous cell carcinoma element. p53 protein was negative in both elements.
  • The present case is the second case of adenosquamous carcinoma arising in congenital choledochal cyst in the English-language literature.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Carcinoma, Adenosquamous / pathology. Choledochal Cyst / pathology
  • [MeSH-minor] Adult. Bile Ducts / pathology. Bile Ducts / surgery. Cholecystectomy. Humans. Immunohistochemistry. Male. Pancreas / pathology. Pancreas / surgery. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563412.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


16. Zhang B, Gao SL: Education of imaging. Hepatobiliary and pancreatic: adenosquamous carcinoma of the pancreas. J Gastroenterol Hepatol; 2008 May;23(5):820
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Education of imaging. Hepatobiliary and pancreatic: adenosquamous carcinoma of the pancreas.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410615.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


17. Bideau K, Metges JP, Bayle S, André M, Robaszkiewicz M, Lagarde N, Labat JP: [Treatment of squamous cell carcinoma of the pancreas with gemcitabine]. Gastroenterol Clin Biol; 2006 Oct;30(10):1217-20
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of squamous cell carcinoma of the pancreas with gemcitabine].
  • Primary squamous cell carcinoma of the pancreas is a rare tumor.
  • We report a case of a 49 years old patient with a metastatic squamous cell carcinoma of the pancreas.
  • Histological diagnosis was established by echoguided biopsy of the liver.
  • Due to that, we cannot be sure that this tumor was not adenosquamous with a metastatic component from only the squamous part of the lesion.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075482.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


18. Ikeda E, Shigematsu T, Hidaka K, Nishikawa A, Katayama M, Okajima T, Kawahara T, Tanaka M, Banba M: [A case of adenosquamous gastric carcinoma successfully treated with TS-1, low-dose CDDP and docetaxel as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2007 Mar;34(3):423-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenosquamous gastric carcinoma successfully treated with TS-1, low-dose CDDP and docetaxel as neoadjuvant chemotherapy].
  • The patient was a 66-year-old male with extremely advanced gastric cancer type 3 and diagnosed with adenocarcinoma by endoscopic biopsies specimens.
  • Therefore, total gastrectomy, partial pancreas body and tail resection, and D 2 lymph node dissection were performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353635.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Basturk O, Khanani F, Sarkar F, Levi E, Cheng JD, Adsay NV: DeltaNp63 expression in pancreas and pancreatic neoplasia. Mod Pathol; 2005 Sep;18(9):1193-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DeltaNp63 expression in pancreas and pancreatic neoplasia.
  • It is not known whether this marker may have any application in another exocrine organ, the pancreas.
  • A total of 25 cases were non-neoplastic pancreata, 25 were pancreatic intraepithelial neoplasia (PanIN) of various grades, and 50 were examples of pancreatic ductal adenocarcinoma.
  • Sections of non-neoplastic pancreata included various types of non-neoplastic processes such as squamous/transitional metaplasia (five cases), which can be mistaken for high-grade PanINs, as well as various degrees of reactive ductal atypia and incidental microcysts with attenuated lining (five cases).
  • No DNp63 expression was noted in normal pancreatic ducts.
  • On the other hand, all five foci of squamous/transitional metaplasia were strongly and uniformly positive for this marker.
  • DNp63 labeling was also noted in those incidental microcysts lined by attenuated cells, seen amidst normal pancreatic lobules.
  • Among invasive carcinomas, DNp63 expression was detected only in areas of squamous differentiation and was completely absent in ordinary ductal areas.
  • Based on this observation, five additional cases of adenosquamous/squamous carcinoma was retrieved and stained, and the squamous components of all of these were also positive.
  • In conclusion, (I) DNp63 is a reliable marker of squamous differentiation in the pancreas.
  • It is valuable in distinguishing squamous/transitional metaplasia from PanINs, a distinction of importance for both researchers and diagnosticians.
  • Among invasive carcinomas, it seems to be entirely specific for areas of squamous differentiation. (II) Those incidental microcysts seen in acinar lobules and lined by attenuated cells are also positive for DNp63, which suggests that they may be metaplastic in nature, and that they do not represent neoplastic cells. (III) Unlike the ducts of other exocrine organs, breast and prostate, there are no DNp63-expressing cells in the normal pancreatic ducts, and therefore, this marker cannot be used in distinguishing invasive carcinomas from the non-invasive ducts. (IV) No p63-expressing 'stem' cells are present in the pancreas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma in Situ / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology. Phosphoproteins / biosynthesis. Trans-Activators / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976814.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / PAR-02-068
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


20. Lahmar A, Abid SB, Arfa MN, Bayar R, Khalfallah MT, Mzabi-Regaya S: Metachronous cancer of gallbladder and pancreas with pancreatobiliary maljunction. World J Gastrointest Surg; 2010 Apr 27;2(4):143-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous cancer of gallbladder and pancreas with pancreatobiliary maljunction.
  • Pancreaticobiliary maljunction is a congenital anomaly in which the junction between the pancreatic duct and the common bile duct is located outside the sphincter of Oddi.
  • It is well known that pancreaticobiliary maljunction is frequently associated with carcinoma of thebiliary tract.
  • We report a case of metachronous cancer of the gallbladder and pancreas associated with pancreaticobiliary maljunction and cystic dilatation of common bile duct in a 68-year-old Tunisian woman who underwent a cholecystectomy for acute cholecystitis.
  • The pancreatic tumor was an adenosquamous carcinoma.
  • Pancreaticobiliary maljunction allows for pancreatobiliary or biliopancreatic reflux which may induce biliary tract carcinoma.
  • The association with pancreatic carcinoma remains rare.
  • Close attention should be given to both the biliary tract system and pancreas during the long-term follow-up of patients with pancreaticobiliary maljunction, especially after they have undergone a choledochojejunostomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160863.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999228
  • [Keywords] NOTNLM ; Gallbladder cancer / Pancreatic cancer / Pancreaticobiliary maljunction
  •  go-up   go-down


21. Akatsu T, Kameyama K, Kawachi S, Tanabe M, Aiura K, Wakabayashi G, Ueda M, Shimazu M, Kitajima M: Gallbladder carcinoma with osteoclast-like giant cells. J Gastroenterol; 2006 Jan;41(1):83-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallbladder carcinoma with osteoclast-like giant cells.
  • These neoplasms are most frequently reported in the breast and pancreas.
  • We report here on an additional case of gallbladder carcinoma with an infiltrate of OGCs.
  • Histological examination showed an adenosquamous carcinoma with an infiltrate of benign OGCs.
  • This case adds to a small body of literature on gallbladder carcinoma with OGCs.
  • Further studies are required to clearly define the prognostic significance of these giant cells in gallbladder cancer and the differences between adenosquamous carcinoma with OGCs and other gallbladder carcinomas (such as adenocarcinoma and squamous cell carcinoma) with those cells.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Gallbladder Neoplasms / pathology. Giant Cells / pathology. Osteoclasts / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):453-9 [7726143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4 [2169622.001]
  • [Cites] Pathol Int. 2003 Jul;53(7):450-6 [12828610.001]
  • [Cites] Breast. 2001 Jun;10(3):231-6 [14965590.001]
  • [Cites] Endocrinology. 1989 Jul;125(1):20-7 [2544401.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1678-81 [10364044.001]
  • [Cites] Cancer. 1988 May 1;61(9):1872-9 [2451557.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):287-93 [6263212.001]
  • [Cites] Hum Pathol. 1992 Jun;23(6):703-6 [1592394.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):228-31; discussion 232-4 [8321752.001]
  • [Cites] Am J Gastroenterol. 1995 Jul;90(7):1177-9 [7611227.001]
  • (PMID = 16501862.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol; 2009 Apr 10;27(11):1806-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.
  • PURPOSE: Contrary to the extensive data accumulated regarding pancreatic carcinogenesis, the clinical and molecular features characteristic of advanced stage (stage III and IV) disease are unknown.
  • A comprehensive study of pancreatic cancers from patients who have succumbed to their disease has the potential to greatly expand our understanding of the most lethal stage of this disease and identify novel areas for intervention.
  • MATERIALS AND METHODS: Rapid autopsies were performed on 76 patients with documented pancreatic cancer.
  • The histologic features of end stage disease were determined and correlated to the stage at initial diagnosis, patterns of failure (locally destructive v metastatic disease) and the status of the KRAS2, TP53, and DPC4 genes.
  • RESULTS: At autopsy, 30% of patients died with locally destructive pancreatic cancer, and 70% died with widespread metastatic disease.
  • However, Dpc4 immunolabeling status of carcinoma tissues harvested at autopsy, a sensitive marker of DPC4 genetic status, was highly correlated with the presence of widespread metastasis but not with locally destructive tumors (P = .007).
  • CONCLUSION: Pancreatic cancers are represented by distinct genetic subtypes with significantly different patterns of failure.
  • Determinations of DPC4 status at initial diagnosis may be of value in stratifying patients into treatment regimens related to local control versus systemic therapy.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):37-43 [10623651.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4115-21 [11751510.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4531-42 [12454109.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2003;4:237-56 [14527303.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8614-22 [14695172.001]
  • [Cites] Int J Gastrointest Cancer. 2003;33(2-3):155-64 [14716065.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1597-604 [15014009.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3025-33 [8187092.001]
  • [Cites] Arch Surg. 1995 Feb;130(2):125-34 [7848081.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4670-5 [7553647.001]
  • [Cites] Pancreas. 1995 Nov;11(4):345-9 [8532650.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Cancer Biol Ther. 2005 May;4(5):548-54 [15846069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13909-14 [16172383.001]
  • [Cites] J Cell Sci. 2005 Oct 15;118(Pt 20):4901-12 [16219695.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2202-9 [16489022.001]
  • [Cites] J Theor Biol. 2006 Aug 7;241(3):676-89 [16497335.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] J Gastrointest Surg. 2006 Nov;10(9):1199-210; discussion 1210-1 [17114007.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1562-7 [17088901.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 7:vii1-vii10 [17600091.001]
  • [Cites] J Gastrointest Surg. 2007 Aug;11(8):1057-77 [17530336.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):173-80 [17667493.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1000-4 [17762890.001]
  • [Cites] Int J Oncol. 2007 Oct;31(4):741-51 [17786304.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):412-8 [18223216.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1455-63 [18316569.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [CommentIn] J Clin Oncol. 2012 May 1;30(13):1564-5; author reply 1566-7 [22412127.001]
  • (PMID = 19273710.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA106610; United States / NCI NIH HHS / CA / P50 CA062924; United States / NCI NIH HHS / CA / CA106610; United States / NCI NIH HHS / CA / CA62924
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2668706
  •  go-up   go-down


23. Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ: Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas; 2008 Aug;37(2):134-8
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry.
  • OBJECTIVES: Although most pancreatic neoplasms are adenocarcinoma, there are many other histological types, some of which may be increasing in frequency.
  • METHODS: Using the State of Michigan tumor registry, all patients with primary pancreatic cancers from 1986 to 2002 were identified, and patients were excluded if there were insufficient data or the histological subtype was not clearly defined in the literature.
  • RESULTS: There were 17,610 pancreatic neoplasms identified, and 2425 were excluded, leaving a final population of 15,185.
  • Twenty-five types of primary pancreatic neoplasms were identified.
  • The most common were adenocarcinoma, mucinous cystadenocarcinoma, nonfunctional neuroendocrine, adenosquamous, anaplastic, intraductal papillary mucinous, and acinar cell (8.37, 0.43, 0.18, 0.05, 0.04, 0.04, and 0.02 per 100,000 per year, respectively).
  • CONCLUSIONS: The incidence of most pancreatic neoplasms has changed a little; however, nonfunctional neuroendocrine neoplasms increased greater than 2-fold.
  • [MeSH-major] Pancreatic Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma, Acinar Cell / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Pancreatic Ductal / epidemiology. Cystadenocarcinoma, Mucinous / epidemiology. Female. Humans. Male. Michigan / epidemiology. Middle Aged. Neuroendocrine Tumors / epidemiology. Registries. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665072.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Takahashi K, Hirano F, Matsumoto K, Aso K, Haneda M: Homeobox gene CDX2 inhibits human pancreatic cancer cell proliferation by down-regulating cyclin D1 transcriptional activity. Pancreas; 2009 Jan;38(1):49-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homeobox gene CDX2 inhibits human pancreatic cancer cell proliferation by down-regulating cyclin D1 transcriptional activity.
  • This study is intended to investigate the effect of CDX2 expression on cell proliferation and cyclin D1 expression in pancreatic cancer cells.
  • METHODS: Four pancreatic ductal adenocarcinoma cell lines (PancQGO-1, BxPC-3, MIAPaCa-2, CFPAC-1), 1 islet carcinoma cell line (QGP-1), and 1 adenosquamous carcinoma cell line (KP-3) were analyzed for CDX1 and CDX2 expression using real-time reverse transcription-polymerase chain reaction and Western blot analysis.
  • Proliferation of pancreatic cancer cells was analyzed using WST-1 assay after CDX2 transfection.
  • Moreover, CDX2 was expressed at a middle level in 4 pancreatic ductal adenocarcinoma cells.
  • Cell proliferation and cyclin D1 mRNA level were inhibited significantly after CDX2 transfection in pancreatic cancer cells.
  • CONCLUSIONS: CDX2 might play a role in inhibiting cell proliferation and repressing cyclin D1 transcriptional activity through the proximal nuclear factor kappaB binding site in pancreatic cancer cells.
  • [MeSH-major] Cell Proliferation. Cyclin D1 / genetics. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Pancreatic Neoplasms / genetics. Transcription, Genetic
  • [MeSH-minor] Carcinoma, Adenosquamous / genetics. Carcinoma, Adenosquamous / pathology. Carcinoma, Islet Cell / genetics. Carcinoma, Islet Cell / pathology. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / pathology. Cell Line, Tumor. Cyclooxygenase 2 / genetics. Down-Regulation. Humans. NF-kappa B / genetics. Promoter Regions, Genetic. RNA, Messenger / metabolism. Time Factors. Transfection

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106744.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / CDX1 protein, human; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / NF-kappa B; 0 / RNA, Messenger; 136601-57-5 / Cyclin D1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


25. Joshita S, Nakazawa K, Sugiyama Y, Kamijo A, Matsubayashi K, Miyabayashi H, Furuta K, Kitano K, Kawa S: Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. Intern Med; 2009;48(9):687-91
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course.
  • Herein, we encountered an 89-year-old woman with pancreatic cancer who presented with fever without infective focus, leukocytosis of 45,860 /microL, and elevation of serum granulocyte-colony stimulating factor (G-CSF).
  • Specimens taken at necropsy revealed an adenosquamous carcinoma positive for G-CSF by immunohistochemistry; it was only the second reported case to date.
  • She was finally diagnosed with G-CSF-producing pancreatic cancer.
  • In light of the above, clinicians should consider the presence of G-CSF-producing tumors, including pancreatic cancer, when presented with patients showing leukocytosis of unknown origin and fever without infective focus.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Granulocyte Colony-Stimulating Factor / biosynthesis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Leukocytosis / diagnosis. Leukocytosis / immunology. Lung Neoplasms / immunology. Lung Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420814.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 27
  •  go-up   go-down


26. Egawa S, Sunamura M, Abe H, Motoi F, Fukuyama S, Matsuno S: [Clinicopathological aspects of pancreatic cancer]. Gan To Kagaku Ryoho; 2005 May;32(5):605-11
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological aspects of pancreatic cancer].
  • Using the nationwide database of the Japan Pancreas Society (JPS), the clinicopathological features of 23,284 cases (1981-2000) and 2,298 cases (2001-2002) with pancreatic neoplasms were compared.
  • The proportion of less differentiated adenocarcinoma was increased in the more advanced stages of the disease.
  • In Stage IVa, the survival of the patients with papillary adenocarcinoma was not statistically different from that of patients with well or moderate tubular adenocarcinoma, though the difference was significant in earlier stages.
  • The survival of the patients with poorly differentiated adenocarcinoma, adenosquamous carcinoma and undifferentiated carcinoma was miserable.
  • Integration of the nationwide registry and pathological information will give new insights for the treatment of pancreatic cancer.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / classification. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Mucinous / mortality. Cystadenocarcinoma, Mucinous / pathology. Humans. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918558.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Lüttges J, Klöppel G: [Pancreatic ductal adenocarcinoma and its precursors]. Pathologe; 2005 Feb;26(1):12-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic ductal adenocarcinoma and its precursors].
  • Pancreatic ductal adenocarcinoma is the most frequent malignant pancreatic tumor.
  • Its morphological characteristics are: preferential localization in the head of the pancreas, ductal-glandular tumor structures combined with marked desmoplasia and CEA and MUC1 positivity.
  • Variants of this carcinoma include adenosquamous carcinomas, undifferentiated pleomorphic carcinomas and mixed ductal-endocrine tumors.
  • With the definition of ductal lesions as pancreatic intraepithelial neoplasia, a progression model for pancreatic ductal carcinoma has been developed and corresponding gene alterations have been detected.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Pancreatic Ductal / pathology. Precancerous Conditions / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Gastroenterol Rep. 2004 Apr;6(2):111-8 [15191688.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;880:210-8 [10415866.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):214-21 [12569143.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):508-17 [12942322.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2):241-50 [8623060.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2690-8 [1277176.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):466-71 [11914624.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):83-92 [10880379.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1641-51 [10793075.001]
  • [Cites] Gastroenterology. 1954 Nov;27(5):629-40 [13210601.001]
  • [Cites] World J Surg. 2000 May;24(5):595-601; discussion 601-2 [10787083.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Pancreatology. 2001;1(6):571-5 [12120238.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1501-7 [9626054.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):173-82 [14692038.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] J Pathol. 2003 Sep;201(1):63-74 [12950018.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] Dig Surg. 1999;16(4):291-6 [10449973.001]
  • [Cites] Pathology. 2003 Feb;35(1):14-24 [12701679.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):165-81 [9443994.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1087-95 [12379756.001]
  • [Cites] Virchows Arch. 1998 Sep;433(3):237-42 [9769127.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • (PMID = 15630571.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1
  •  go-up   go-down


28. Benzoni E, Saccomano E, Zompicchiatti A, Lorenzin D, Baccarani U, Adani GL, Uzzau A, Noce L, Cedolini C, Bresadola F, De Anna D, Intini S: The role of pancreatic leakage on rising of postoperative complications following pancreatic surgery. J Surg Res; 2008 Oct;149(2):272-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of pancreatic leakage on rising of postoperative complications following pancreatic surgery.
  • INTRODUCTION: The variations in methods of pancreatic stump management and the volume of literature available on both main pancreatic duct and pancreaticoenetric anastomosis leak indicates the concern associated with the leak and the continuing efforts to prevent it.
  • Herein we analyzed the role of pancreatic leakage followed by pancreatic surgery on the incidence of postoperative morbidity.
  • RESULTS: In the PD group, morbidity rate was 60%, caused by pancreatic leakage, with an incidence of 48%, hemorrhagic complication, occurred in 10% of patients following surgical procedure and infectious complication, with an incidence of 15%.
  • By multivariate analysis bleeding complications, biliary anastomosis leakage, and infectious complications were consequences of pancreatic leakage (P = 0.025, P = 0.025, and P = 0.025, respectively).
  • CONCLUSIONS: On the ground of our results of bleeding complication, biliary anastomosis leakage and infectious complication were consequences of pancreatic leakage: failure of a surgical anastomosis has serious consequences, particularly in case of anastomosis of the pancreas to the small bowel, because of the digestive capacities of activated pancreatic secretions.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Cystadenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery. Postoperative Complications / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17997415.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Takano S, Yoshitomi H, Togawa A, Sogawa K, Shida T, Kimura F, Shimizu H, Tomonaga T, Nomura F, Miyazaki M: Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells. Oncogene; 2008 May 1;27(20):2810-22
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells.
  • Pancreatic cancer still remains one of the most lethal diseases and establishment of new therapy is needed.
  • The purpose of this study is to find novel factors involved in pancreatic cancer progression by proteomic approach.
  • We compared pre- and postoperative serum protein profiling obtained from pancreatic cancer patients who had curative pancreatectomy using surface-enhanced laser desorption ionization time-of-flight mass spectrometry.
  • Furthermore, ApoC-1 was abundantly expressed in pancreas neoplastic epithelium, and was detected in the culture medium of the pancreatic cancer cell line in vitro, which suggests that cancer cells secrete ApoC-1.
  • Inhibition of ApoC-1 expression by short interfering RNA suppressed cell proliferation and induced apoptosis of pancreatic cancer cells.
  • The specific expression of ApoC-1 and its role in preventing from spontaneous apoptosis in pancreatic cancer cells suggest that ApoC-1 contributes to the aggressiveness of pancreatic cancer and will be useful as a new therapeutic target.
  • [MeSH-major] Apolipoprotein C-I / physiology. Apoptosis / physiology. Cell Survival / physiology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / chemistry. Carcinoma, Adenosquamous / metabolism. Carcinoma, Adenosquamous / pathology. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037960.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apolipoprotein C-I; 0 / Biomarkers, Tumor
  •  go-up   go-down


30. Jung KW, Kim MH, Lee TY, Kwon S, Oh HC, Lee SS, Seo DW, Lee SK: Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer. J Korean Med Sci; 2007 Sep;22 Suppl:S79-85
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological aspects of 542 cases of pancreatic cancer: a special emphasis on small pancreatic cancer.
  • Small pancreatic cancers (longest diameter </=2 cm) have been regarded as preliminary to early pancreatic cancer, which was thought to be highly curable.
  • During our experience since 1989, we evaluated 542 cases of pancreatic cancer.
  • Among them we found 74 cases of tumors </=2 cm in diameter, small pancreatic cancer (TS1 pancreatic cancer).
  • Well-differentiated adenocarcinomas (18.9%) and absence of symptoms (8.1%) were more frequent in patients with TS1 than in those with larger pancreatic tumors.
  • Only 16 of the 74 patients (21.6%) with small pancreatic cancers had T1 tumors.
  • These findings may indicate that 'small' pancreatic cancer is not equivalent to 'early' pancreatic cancer.
  • [MeSH-major] Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Adult. Aged. CA-19-9 Antigen / metabolism. Carcinoembryonic Antigen / metabolism. Carcinoma / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Pancreatic Ductal / pathology. Female. Humans. Korea / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tumor Burden

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Surg. 2001;18(1):41-6 [11244258.001]
  • [Cites] Nihon Rinsho. 2006 Jan;64 Suppl 1:165-9 [16457242.001]
  • [Cites] Pancreatology. 2001;1(6):597-603 [12120242.001]
  • [Cites] Hepatogastroenterology. 2003 Nov-Dec;50(54):2218-24 [14696502.001]
  • [Cites] Pancreas. 2004 Apr;28(3):231-4 [15084962.001]
  • [Cites] Pancreas. 2004 Apr;28(3):235-40 [15084963.001]
  • [Cites] Pancreas. 2004 Apr;28(3):263-7 [15084968.001]
  • [Cites] Ann Surg. 1986 Jan;203(1):77-81 [3942423.001]
  • [Cites] Pancreas. 1986;1(3):219-23 [3554223.001]
  • [Cites] Dig Dis Sci. 1988 Oct;33(10):1223-5 [3168694.001]
  • [Cites] Am J Gastroenterol. 1990 Apr;85(4):350-5 [2183589.001]
  • [Cites] Radiology. 1991 Jan;178(1):95-9 [1984331.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):57-62 [8646727.001]
  • [Cites] Pancreas. 1998 Apr;16(3):396-401 [9548685.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(2):128-32 [9745077.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):450-4 [9931396.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):8-15 [10228758.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1941-6 [10406263.001]
  • [Cites] Surg Gynecol Obstet. 1964 Feb;118:275-83 [14119102.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • (PMID = 17923760.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  • [Other-IDs] NLM/ PMC2694379
  •  go-up   go-down


31. Bergmann F, Aulmann S, Wente MN, Penzel R, Esposito I, Kleeff J, Friess H, Schirmacher P: Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol; 2006 Jun;59(6):580-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40.
  • BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) rarely affects people under 40.
  • Pathomorphologically, tumours in three patients displayed moderate differentiation and four showed poor differentiation including one adenosquamous carcinoma.
  • The existence of yet undefined initiating events of pancreatic carcinogenesis is suggested by the low rate of K-ras mutations, in at least a subgroup of young patients.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / genetics. Pancreatic Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Lancet. 1977 Apr 23;1(8017):911 [67325.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):738-44 [11297271.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1677-83 [11337365.001]
  • [Cites] Biol Cell. 2001 Sep;93(1-2):53-62 [11730323.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4115-21 [11751510.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4531-42 [12454109.001]
  • [Cites] Cancer Detect Prev. 2003;27(2):87-93 [12670518.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2585-8 [12750283.001]
  • [Cites] Am J Surg Pathol. 1983 Jun;7(4):319-27 [6307069.001]
  • [Cites] J Pediatr Surg. 1985 Apr;20(2):184-5 [4009367.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):97-9 [3943856.001]
  • [Cites] Am J Gastroenterol. 1986 Jul;81(7):594-7 [3717125.001]
  • [Cites] Cancer. 1987 May 1;59(9):1661-4 [3828965.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Am J Med Genet. 1989 Jan;32(1):1-8 [2705469.001]
  • [Cites] Mol Cell Biol. 1989 Jul;9(7):3114-6 [2674680.001]
  • [Cites] Trop Gastroenterol. 1994 Apr-Jun;15(2):99-103 [7831723.001]
  • [Cites] Conn Med. 1995 May;59(5):259-62 [7600796.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):589-92 [8625151.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1731-4 [9135016.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] Am J Surg Pathol. 1999 Mar;23(3):323-8 [10078924.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1821-5 [10854204.001]
  • [Cites] Cancer Lett. 2003 Sep 25;199(2):169-73 [12969789.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1255-60 [14507635.001]
  • [Cites] Pancreas. 2003 Oct;27(3):e57-62 [14508142.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5669-73 [14522881.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):173-82 [14692038.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:15 [12605716.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Gastroenterology. 1974 May;66(5):1054-7 [4524208.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(4):280-2 [10473729.001]
  • (PMID = 16497872.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1860388
  •  go-up   go-down


32. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T, Tanaka M: Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia; 2010 Oct;12(10):807-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
  • BACKGROUND AND AIMS: The standard palliative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is gemcitabine-based chemotherapy; however, PDAC still presents a major therapeutic challenge.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Biomarkers, Tumor / genetics. Carcinoma, Adenosquamous / drug therapy. Deoxycytidine / analogs & derivatives. Gene Expression Regulation, Neoplastic / physiology. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):32-42 [17194903.001]
  • [Cites] N Engl J Med. 2007 Feb 22;356(8):800-8 [17314339.001]
  • [Cites] Dig Surg. 2007;24(2):137-47 [17476103.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Feb;324(2):558-67 [18042828.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):674-9 [18592007.001]
  • [Cites] Anticancer Res. 2008 Jul-Aug;28(4B):2205-12 [18751396.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2244-51 [18795940.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):187-95 [18992248.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2913-9 [19318496.001]
  • [Cites] Neoplasia. 2009 Jul;11(7):712-9 [19568416.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Oncogene. 2009 Aug 13;28(32):2903-9 [19543324.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):122-30 [10623702.001]
  • [Cites] Trends Pharmacol Sci. 2001 Aug;22(8):420-6 [11479005.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3263-8 [11595723.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):34-41 [12552078.001]
  • [Cites] Semin Surg Oncol. 2003;21(1):19-22 [12923912.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):5000-8 [14581375.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 1;66(11):2185-91 [14609743.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1539-48 [14661056.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3215-22 [15126362.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4215s-4219s [15217961.001]
  • [Cites] Pharmacogenomics J. 2004;4(5):307-14 [15224082.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6956-61 [15501974.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):533-9 [1732039.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1165-9 [9515801.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4349-57 [9766663.001]
  • [Cites] Cancer Lett. 1999 Aug 3;142(2):129-37 [10463768.001]
  • [Cites] Gut. 2005 Mar;54(3):385-7 [15710987.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2285-92 [15788678.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):35-40 [15986033.001]
  • [Cites] Lung Cancer. 2005 Sep;49(3):363-70 [15923058.001]
  • [Cites] Lab Invest. 2005 Aug;85(8):1040-50 [15951835.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3928-35 [16585222.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2492-7 [16638857.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1355-63 [17131328.001]
  • (PMID = 20927319.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Equilibrative Nucleoside Transporter 1; 0 / RNA, Messenger; 0 / RRM1 protein, human; 0 / SLC29A1 protein, human; 0 / Tumor Suppressor Proteins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / ribonucleotide reductase M2; EC 1.17.4.1 / Ribonucleoside Diphosphate Reductase; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.5.4.5 / Cytidine Deaminase
  • [Other-IDs] NLM/ PMC2950330
  •  go-up   go-down


33. Kashiwazaki M, Takeda Y, Hasuike Y, Masuda N, Ikenaga M, Hirao M, Fujitani K, Mishima H, Sawamura T, Nakamori S, Takeda M, Mano Y, Tsujinaka T: [A case of successful resection for recurrent intraductal papillary mucinous adenocarcinoma]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1863-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful resection for recurrent intraductal papillary mucinous adenocarcinoma].
  • Intraductal papillary-mucinous neoplasms (IPMN) of the pancreas have recently been defined and classified by the World Health Organization.
  • We report a case of a 65-year-old female who underwent surgical resection of the pancreas twice within a period of 6 months for primary and recurrent IPMN.
  • A histopathological study revealed invasive adenocarcinoma and the negative margin of the pancreatic duct.
  • Recurrent IPMN consisted of adenosquamous cell carcinoma.
  • Recurrent disease in the residual pancreas suggests that a long-term surveillance is critical.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / surgery. Pancreatic Ducts. Pancreatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315964.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Kosmahl M, Pauser U, Anlauf M, Klöppel G: Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform. Mod Pathol; 2005 Sep;18(9):1157-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform.
  • Cystic tumors of the pancreas are uncommon but important because of their diverse pathology and biology.
  • In this study, we screened pancreatic ductal adenocarcinomas and their variants for macrocystic changes and determined the nature of the cysts (neoplastic vs non-neoplastic).
  • The largest group consisted of 24 pancreatic ductal adenocarcinomas showing a large-gland pattern with small cysts whose diameter varied between 0.5 and 1.8 cm.
  • This group consisted of poorly differentiated pancreatic ductal adenocarcinomas, undifferentiated carcinomas with or without osteoclast-like giant cells and one adenosquamous carcinoma.
  • In the third group of cystic tumors there were four pancreatic ductal adenocarcinomas containing tumor-related retention cysts.
  • The fourth group consisted of two pancreatic ductal adenocarcinomas showing closely attached pseudocysts caused by tumor-associated pancreatitis.
  • The results indicate that a considerable number of pancreatic ductal adenocarcinomas and their variants display cystic features and must therefore be considered in the differential diagnosis of cystic neoplasms of the pancreas.
  • [MeSH-major] Carcinoma, Pancreatic Ductal / pathology. Cysts / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920540.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


35. Grizzle WE, Srivastava S, Manne U: The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark; 2010;9(1-6):21-39
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) microinvasive disease developing from a pre-invasive neoplastic lesion, 2) the general association of the pre-invasive lesion with invasive lesions, 3) the subsequent development of invasive lesions following diagnosis of the pre-invasive lesion, 4) correlations of the molecular features of the putative pre-invasive lesion with the matching invasive lesions, and 5) reductions in the rate of cancer following removal of the pre-invasive lesion.
  • Thus, adoption of these terms for the additional organ sites of pancreas (PanIN) and prostate (PIN) seems accepted.
  • An excellent example of this is ulcerative colitis (UC) in which dysregulation of microsatellite repair enzymes have been documented one year following diagnosis of UC.
  • While the nomenclature, description, diagnosis and etiology of pre-invasive neoplasia has advanced, approaches to therapy of such lesions have not progressed adequately even though it has been identified that, for example, removal of polyps periodically from the colorectum, DCIS from the breast, and high grade CIN from the cervix, results in a reduction in the development of cancers of the colorectum, breast, and cervix, respectively.
  • [MeSH-major] Carcinoma in Situ / etiology
  • [MeSH-minor] Animals. Carcinoma, Adenosquamous / etiology. Carcinoma, Squamous Cell / etiology. Cell Transformation, Neoplastic / chemically induced. Cell Transformation, Neoplastic / radiation effects. Disease Progression. Environmental Exposure. Humans. Immunologic Surveillance. Metagenome. Mice. Neoplasm Regression, Spontaneous. Neoplasms, Experimental / etiology. Neoplastic Stem Cells / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem Suppl. 1994;19:259-66 [7823598.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):751-8 [6275978.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4264-7 [7671233.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1237-40 [8640805.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1197-200 [8630897.001]
  • [Cites] Eur Urol. 1996;30(2):153-66 [8875196.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]
  • [Cites] J Histochem Cytochem. 2008 Mar;56(3):305-12 [18071066.001]
  • [Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2813-20 [18539959.001]
  • [Cites] Pathobiology. 2008;75(2):75-84 [18544962.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1361-5 [18703712.001]
  • [Cites] JAMA. 2008 Oct 1;300(13):1523-31 [18827209.001]
  • [Cites] N Engl J Med. 1985 Jan 17;312(3):146-51 [3965932.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):64-71 [3943853.001]
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1076-9 [3778125.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]
  • [Cites] Carcinogenesis. 1990 Aug;11(8):1393-8 [2167183.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):644-52 [1712748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1621-6 [10362784.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1825-30 [10362807.001]
  • [Cites] Head Neck. 1999 Sep;21(6):566-73 [10449674.001]
  • [Cites] Jpn J Cancer Res. 1999 Jul;90(7):711-9 [10470282.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1375-85 [16424164.001]
  • [Cites] Lab Invest. 2006 Feb;86(2):175-90 [16402033.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R897-908 [16280039.001]
  • [Cites] Nat Med. 2006 Aug;12(8):875-8 [16892025.001]
  • [Cites] Blood. 2007 May 15;109(10):4336-42 [17244679.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6867-75 [17513735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13732-7 [17702869.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8121-30 [17804724.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3407-16 [17666570.001]
  • [Cites] Nat Med. 1997 May;3(5):510-4 [9142118.001]
  • [Cites] Biotech Histochem. 1997 Mar;72(2):96-104 [9152522.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Jul;19(3):170-5 [9218998.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 1;90(7):523-31 [9539248.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):597-9 [10203598.001]
  • [Cites] Hum Pathol. 1993 Mar;24(3):298-310 [8454275.001]
  • [Cites] J Invest Dermatol. 1993 Jun;100(6):746-8 [8496613.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1994 Jan 20;330(3):159-64 [8264737.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):765-78 [8037290.001]
  • [Cites] J Immunol. 2008 Oct 15;181(8):5242-8 [18832678.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Breast Dis. 2008;29:27-36 [19029622.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):678-86 [19147584.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1302-13 [19190339.001]
  • [Cites] Nat Rev Immunol. 2009 Mar;9(3):162-74 [19197294.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2621-33 [19235923.001]
  • [Cites] Cancer Biomark. 2010;9(1-6):41-64 [22112469.001]
  • [Cites] Cancer Biomark. 2010;9(1-6):177-92 [22112476.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1985-92 [10595928.001]
  • [Cites] J Immunol Methods. 2001 Jan 1;247(1-2):163-74 [11150547.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3230-9 [11309271.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1247-53 [11583952.001]
  • [Cites] Gut. 2002 Apr;50(4):520-4 [11889073.001]
  • [Cites] Nat Rev Immunol. 2002 Aug;2(8):569-79 [12154376.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):149-58 [12168960.001]
  • [Cites] Immunol Allergy Clin North Am. 2003 Feb;23(1):83-102, vi [12645880.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6369-76 [14508517.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3112-26 [14681207.001]
  • [Cites] Am J Gastroenterol. 1995 Mar;90(3):353-65 [7872270.001]
  • (PMID = 22112468.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / P30 AR050948; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P50 CA101955; United States / NCI NIH HHS / CA / U24 CA086359
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS402045; NLM/ PMC3430522
  •  go-up   go-down


36. Izuishi K, Takebayashi R, Suzuki Y: Electronic image of the month. Adenosquamous carcinoma of the pancreas. Clin Gastroenterol Hepatol; 2010 Apr;8(4):e40
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electronic image of the month. Adenosquamous carcinoma of the pancreas.
  • [MeSH-major] Carcinoma, Adenosquamous / diagnosis. Carcinoma, Adenosquamous / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20005983.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Okamura Y, Sugimoto H, Fujii T, Nomoto S, Takeda S, Nakao A: Adenosquamous carcinoma arising in an intraductal papillary mucinous neoplasm of the pancreas. Pancreas; 2010 Aug;39(6):945-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma arising in an intraductal papillary mucinous neoplasm of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Carcinoma, Adenosquamous / diagnosis. Carcinoma, Pancreatic Ductal / complications. Carcinoma, Papillary / complications. Pancreatic Neoplasms / complications
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Pancreas / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664487.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  •  go-up   go-down






Advertisement